R-1530

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NameR-1530

Drug Alias NameR-1530RG1530RG-1530

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 1 antagonists +[7]

TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Platelet-derived growth factor receptor beta +[7]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesF. Hoffmann-La Roche Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A